MQS Management LLC Acquires New Position in Hologic, Inc. (NASDAQ:HOLX)

MQS Management LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,380 shares of the medical equipment provider's stock, valued at approximately $394,000.

Other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in Hologic in the fourth quarter worth $49,000. Allworth Financial LP boosted its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares in the last quarter. West Financial Advisors LLC acquired a new position in shares of Hologic in the 1st quarter valued at $50,000. Finally, Covestor Ltd grew its holdings in shares of Hologic by 49.3% in the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after buying an additional 341 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

HOLX has been the topic of several research analyst reports. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Royal Bank Of Canada lowered their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Evercore ISI boosted their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Finally, Morgan Stanley dropped their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $78.75.

Insiders Place Their Bets

In related news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Down 1.7%

Hologic stock opened at $65.72 on Monday. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a fifty day simple moving average of $61.55 and a 200 day simple moving average of $63.41. The company has a market cap of $14.65 billion, a P/E ratio of 27.73, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.03 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.